newsfilter
← Latest News
GlobeNewswire·

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today